Aesthetic surgery journalOct 14, 2026

Facial Changes Linked to Glucagon-Like Peptide-1 Receptor Agonists: Causes, Symptoms, Risks, Prevention, and Treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 15, 2026

Abstract

A median 9% reduction in midfacial volume was observed in 20 patients following weight loss with glucagon-like peptide-1 receptor agonists.

Greater volume loss occurred in superficial facial compartments (11%) compared to deeper ones (7%).
Regression analysis estimated approximately 7% total midfacial volume loss for every 10 kg of weight lost.
A survey of 1,226 participants indicated more reports of facial volume loss and laxity correlated with greater percentage weight loss.
Post-bariatric studies report facial deflation and increased apparent age, particularly in older patients and after significant weight loss.
Current evidence suggests weight-loss-associated facial changes may be influenced by baseline anatomy and aging.
The independent effects of weight-loss rate, menopause, and hormone therapy on facial changes remain uncertain.

Simplified

Facial hollowing, skin laxity, and more prominent folds are increasingly reported during weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The term 'Ozempic face' can imply a drug-specific adverse effect, although similar changes occur after other forms of substantial weight loss. This review examines the clinical evidence, proposed mechanisms, and implications for aesthetic care. PubMed, Embase, Web of Science, and Google Scholar were searched for January 2014 through August 2026. Selection was reported using PRISMA 2020 where applicable, followed by narrative synthesis. Of 958 records, 46 reports were included. Serial imaging in 20 patients showed a median 9% reduction in midfacial volume, with greater loss in superficial than deep compartments (11% vs 7%). Regression estimated approximately 7% total midfacial volume loss per 10 kg lost. A FACE-Q short-form has been validated, and a survey of 1,226 participants found more reports of facial volume loss and laxity with greater percentage weight loss. Post-bariatric studies also describe facial deflation and increased apparent age, particularly in older patients and after larger losses. Current evidence favors weight-loss-associated deflation superimposed on baseline anatomy and aging. The independent effect of weight-loss rate and the modifying roles of menopause and hormone therapy remain uncertain. Aesthetic treatment evidence is limited and largely uncontrolled.

Full Text

Full text is available at the source.

View Full Text ↗

Facial Changes Linked to Glucagon-Like Peptide-1 Receptor Agonists: Causes, Symptoms, Risks, Prevention, and Treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief